Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.4161/viru.23987

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717487

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response

Sarah Schmidt Grant¹²³ and Deborah T. Hung¹²³⁴

¹Broad Institute of MIT and Harvard; Cambridge, MA USA; ²Division of Pulmonary and Critical Care Medicine; Department of Medicine; Brigham and Women’s Hospital; Boston, MA USA; ³Department of Microbiology and Immunobiology; Harvard Medical School; Boston, MA USA; ⁴Department of Molecular Biology and Center for Computational and Integrative Biology; Massachusetts General Hospital; Boston, MA USA

Keywords: persistent bacterial infections, antibiotic tolerance, persisters, oxidative stress, small colony variants, biofilms

Certain bacterial pathogens are able to evade the host immune system and persist within the human host. The consequences of persistent bacterial infections potentially include increased morbidity and mortality from the infection itself as well as an increased risk of dissemination of disease. Eradication of persistent infections is difficult, often requiring prolonged or repeated courses of antibiotics. During persistent infections, a population or subpopulation of bacteria exists that is refractory to traditional antibiotics, possibly in a non-replicating or metabolically altered state. This review highlights the clinical significance of persistent infections and discusses different in vitro models used to investigate the altered physiology of bacteria during persistent infections. We specifically focus on recent work establishing increased protection against oxidative stress as a key element of the altered physiologic state across different in vitro models and pathogens.

Introduction

For many bacterial pathogens, the host immune system successfully eliminates the invading bacteria and the infection resolves. In certain infections, however, bacteria evade the host immune system and persist within the host. In some cases these persistent infections are asymptomatic for long periods of time, but can undergo future reactivation into clinically significant disease, or can be associated with malignancy or subsequent disease dissemination. Alternatively, some persistent infections result in clinically apparent, chronic symptoms. In these cases, even standard treatment with antibiotics often fails to effectively sterilize persistent infections, and prolonged or repeated courses of antibiotics are required for successful eradication. At an extreme, lifelong chronic suppression with antibiotics can be required in the absence of eradication.

Many factors contribute to the ability of pathogens to establish persistent infections, including both host and bacterial factors. Certain pathogens appear uniquely adapted to evade the host immune system and persist in infected individuals for decades in the absence of symptoms, for example Mycobacterium tuberculosis or Salmonella Typhi.¹² Other pathogens like Pseudomonas aeruginosa or Escherichia coli can cause both symptomatic acute and chronic infections, with specific changes in the host facilitating the establishment of a persistent infection. The first section of this review highlights the clinical significance of persistent infections and the wide range of strategies employed by bacteria to survive the host immune system response (see Table 1 for examples of bacteria associated with persistent infections). In the second section, we discuss different in vitro models used to investigate the physiology of bacteria involved in persistent infections. Despite differences, many models share a common theme: bacteria adapt to environmental stresses imposed by the host by entering a different physiologic state. A key element of this different physiologic state is a non-replicating or slowly replicating growth rate, which may have the additional benefit of contributing to a pathogen’s defense against antibiotic exposure. Walsh McDermott first suggested in the 1950s that the relative metabolic state of bacteria affects antibiotic efficacy, causing cells to become “indifferent” to antibiotics, thereby relating the physiologic state of bacteria to antibiotic efficacy.³

One of the most significant environmental stresses encountered by bacteria is the host oxidative immune response. In addition, studies have suggested that treatment with bactericidal antibiotics may result in increased oxidative stress via the Fenton reaction, though this finding remains controversial with more recent studies questioning this mechanism of cell death.⁴⁻⁹ Increased antioxidant capabilities may therefore protect a bacterium from both the host immune response as well as antibiotic therapy. In this review we specifically focus on recent work demonstrating the role of increased defenses against oxidative stress in various in vitro models for persistent infections. Increased antioxidant capabilities may protect a bacterium from the host immune response as well as facilitate survival during antibiotic exposure, thereby enabling the establishment of a persistent infection.

Clinical Significance of Persistent Infections

Asymptomatic persistent infections. Several persistent infections are clinically asymptomatic yet still have significant consequences for their human host. In some cases these consequences represent an increased risk of developing clinically significant disease at a later time, exemplified by M. tuberculosis and Treponema
the innate and adaptive immune response is able to successfully sterilize the lungs, resulting in the creation of a long-term reservoir. The immune response is unable, however, to completely contain the infection in the lungs by forming well-organized structures called granulomas, containing a reservoir of live bacteria. The immune response is unable, however, to completely sterilize the lungs, resulting in the creation of a long-term reservoir of bacteria. An individual with latent *M. tuberculosis* infection can remain asymptomatic for decades, but has a 10% risk of developing symptomatic and infectious disease over the course of their lifetime. The risk of developing active disease increases if the immune system becomes compromised, for example, from HIV, cancer chemotherapy or treatment with a tumor necrosis factor (TNF) inhibitor. Similar to *M. tuberculosis*, *T. pallidum*, and *H. pylori*, the consequences of a persistent infection with devastating consequences. In CF patients, mutations in the cystic fibrosis transmembrane regulator protein can persist for decades with the bacterium employing several strategies to evade the host immune system.

### Table 1. Pathogens associated with persistent bacterial infections

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Persistent disease</th>
<th>Biologic mechanisms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asymptomatic persistent infections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>Latent tuberculosis</td>
<td>Intraacellular growth, persisters</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em></td>
<td>Gastritis, gastric cancer</td>
<td>Intraacellular growth</td>
</tr>
<tr>
<td><em>Salmonella Typhi</em></td>
<td>Chronic carrier, gall bladder carcinoma</td>
<td>Intraacellular growth, biofilm formation</td>
</tr>
<tr>
<td><em>Treponema pallidum</em></td>
<td>Latent syphilis</td>
<td>Intraacellular growth</td>
</tr>
<tr>
<td><strong>Symptomatic persistent infections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>Bronchiectasis/pneumonia in CF patients</td>
<td>Biofilms, small colony variants, persisters</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Recurrent urinary tract infections</td>
<td>Intraacellular growth, biofilms</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Bronchiectasis/pneumonia in CF patients; device-associated infections</td>
<td>Biofilms, small colony variants</td>
</tr>
<tr>
<td><em>Hemophilus influenza</em></td>
<td>Recurrent otitis media</td>
<td>Biofilms</td>
</tr>
<tr>
<td><em>Mycobacterium leprae</em></td>
<td>Leprosy</td>
<td>Intraacellular growth</td>
</tr>
</tbody>
</table>

*pallidum*, the causative agents of tuberculosis and syphilis, respectively. In 95% of patients infected with *M. tuberculosis*, the innate and adaptive immune response is able to successfully contain bacterial growth and a clinically silent or latent infection results. Macrophages, monocytes, and T cells are recruited to contain the infection in the lungs by forming well-organized structures called granulomas, containing a reservoir of live bacteria. The immune response is unable, however, to completely sterilize the lungs, resulting in the creation of a long-term reservoir of bacteria. An individual with latent *M. tuberculosis* infection can remain asymptomatic for decades, but has a 10% risk of developing symptomatic and infectious disease over the course of their lifetime. The risk of developing active disease increases if the immune system becomes compromised, for example, from HIV, cancer chemotherapy or treatment with a tumor necrosis factor (TNF) inhibitor. Similar to *M. tuberculosis*, *T. pallidum*, and *H. pylori*, the consequences of a persistent infection with devastating consequences. In CF patients, mutations in the cystic fibrosis transmembrane regulator protein can persist for decades with the bacterium employing several strategies to evade the host immune system.

In other asymptomatic persistent infections, the consequences of infection can include increased risk of malignancy and dissemination of disease. *Helicobacter pylori* is a gram-negative pathogen that can colonize the gastric epithelium, resulting in an asymptomatic, superficial chronic gastritis. *H. pylori* infection can persist for decades with the bacterium employing several strategies to evade the host immune system, including suppressing the adaptive immune response and adapting to an intracellular environment during part of its lifecycle. The consequences of *H. pylori* infection include increased risk of duodenal and peptic ulcers as well as an increased risk of gastric adenocarcinoma and gastric lymphoma. Finally, in the case of *Salmonella Typhi*, an asymptomatic, persistent infection in the gallbladder may occur following an acute episode of typhoid fever or even in the absence of a clinical history of typhoid fever. These asymptomatic carriers shed *Salmonella Typhi* bacteria in their stools and urine without any apparent signs of disease, exemplified by the historic case of Typhoid Mary, infecting other individuals and causing symptomatic disease. Thus, asymptomatic carriers represent a significant public health hazard. In addition, *Salmonella Typhi* infection in the gallbladder is associated with an increased risk of carcinoma of the gallbladder.

**Symptomatic persistent infections.** In contrast to clinically asymptomatic persistent infections, some persistent infections are associated with clinically apparent symptoms at the time of or intermittently during infection. Many symptomatic persistent infections are associated with changes in the host that facilitate the establishment of a persistent infection, for example, the insertion of a foreign device. Device associated infections represent one of the most common forms of persistent infections. It is estimated that more than 50% of hospital-acquired infections are due to infected medical devices, including prosthetic joints, central venous catheters (CVCs), and prosthetic heart valves. Prosthetic joint infections are often very difficult to diagnose, as the patient may present with pain as the only complaint, and diagnostic aspiration of the joint may be unrevealing. The mortality rate for infected prosthetic hip and knee joints is reported to be as high as 2.5% and treatment often requires operative debridement of the joint, possibly including removal of the prosthesis, combined with long-term intravenous antibiotic treatment.

The estimated cost for treating an infected prosthetic joint is $50,000, representing a significant burden on the healthcare system. In the case of CVCs, catheters are rapidly colonized with skin organisms after insertion into the body, complicating diagnosis of CVC-associated infections. While colonization does not uniformly result in disease, colonization increases the risk that bacteria may spread hematogenously, resulting in symptomatic bloodstream infections or secondary infections like endocarditis. It is estimated that there are 80,000 episodes of catheter-related bloodstream infections annually in the US.

Infection in patients with cystic fibrosis (CF) is another example of a persistent infection with devastating consequences. In CF patients, mutations in the cystic fibrosis transmembrane regulator protein can result in increased risk of duodenal and peptic ulcers as well as an increased risk of gastric adenocarcinoma and gastric lymphoma. Finally, in the case of *Salmonella Typhi*, an asymptomatic, persistent infection in the gallbladder may occur following an acute episode of typhoid fever or even in the absence of a clinical history of typhoid fever. These asymptomatic carriers shed *Salmonella Typhi* bacteria in their stools and urine without any apparent signs of disease, exemplified by the historic case of Typhoid Mary, infecting other individuals and causing symptomatic disease. Thus, asymptomatic carriers represent a significant public health hazard. In addition, *Salmonella Typhi* infection in the gallbladder is associated with an increased risk of carcinoma of the gallbladder.

**Symptomatic persistent infections.** In contrast to clinically asymptomatic persistent infections, some persistent infections are associated with clinically apparent symptoms at the time of or intermittently during infection. Many symptomatic persistent infections are associated with changes in the host that facilitate the establishment of a persistent infection, for example, the insertion of a foreign device. Device associated infections represent one of the most common forms of persistent infections. It is estimated that more than 50% of hospital-acquired infections are due to infected medical devices, including prosthetic joints, central venous catheters (CVCs), and prosthetic heart valves. Prosthetic joint infections are often very difficult to diagnose, as the patient may present with pain as the only complaint, and diagnostic aspiration of the joint may be unrevealing. The mortality rate for infected prosthetic hip and knee joints is reported to be as high as 2.5% and treatment often requires operative debridement of the joint, possibly including removal of the prosthesis, combined with long-term intravenous antibiotic treatment.

The estimated cost for treating an infected prosthetic joint is $50,000, representing a significant burden on the healthcare system. In the case of CVCs, catheters are rapidly colonized with skin organisms after insertion into the body, complicating diagnosis of CVC-associated infections. While colonization does not uniformly result in disease, colonization increases the risk that bacteria may spread hematogenously, resulting in symptomatic bloodstream infections or secondary infections like endocarditis. It is estimated that there are 80,000 episodes of catheter-related bloodstream infections annually in the US.

Infection in patients with cystic fibrosis (CF) is another example of a persistent infection with devastating consequences. In CF patients, mutations in the cystic fibrosis transmembrane regulator protein can persist for decades with the bacterium employing several strategies to evade the host immune system, including suppressing the adaptive immune response and adapting to an intracellular environment during part of its lifecycle. The consequences of *H. pylori* infection include increased risk of duodenal and peptic ulcers as well as an increased risk of gastric adenocarcinoma and gastric lymphoma. Finally, in the case of *Salmonella Typhi*, an asymptomatic, persistent infection in the gallbladder may occur following an acute episode of typhoid fever or even in the absence of a clinical history of typhoid fever. These asymptomatic carriers shed *Salmonella Typhi* bacteria in their stools and urine without any apparent signs of disease, exemplified by the historic case of Typhoid Mary, infecting other individuals and causing symptomatic disease. Thus, asymptomatic carriers represent a significant public health hazard. In addition, *Salmonella Typhi* infection in the gallbladder is associated with an increased risk of carcinoma of the gallbladder.

**Symptomatic persistent infections.** In contrast to clinically asymptomatic persistent infections, some persistent infections are associated with clinically apparent symptoms at the time of or intermittently during infection. Many symptomatic persistent infections are associated with changes in the host that facilitate the establishment of a persistent infection, for example, the insertion of a foreign device. Device associated infections represent one of the most common forms of persistent infections. It is estimated that more than 50% of hospital-acquired infections are due to infected medical devices, including prosthetic joints, central venous catheters (CVCs), and prosthetic heart valves. Prosthetic joint infections are often very difficult to diagnose, as the patient may present with pain as the only complaint, and diagnostic aspiration of the joint may be unrevealing. The mortality rate for infected prosthetic hip and knee joints is reported to be as high as 2.5% and treatment often requires operative debridement of the joint, possibly including removal of the prosthesis, combined with long-term intravenous antibiotic treatment.

The estimated cost for treating an infected prosthetic joint is $50,000, representing a significant burden on the healthcare system. In the case of CVCs, catheters are rapidly colonized with skin organisms after insertion into the body, complicating diagnosis of CVC-associated infections. While colonization does not uniformly result in disease, colonization increases the risk that bacteria may spread hematogenously, resulting in symptomatic bloodstream infections or secondary infections like endocarditis. It is estimated that there are 80,000 episodes of catheter-related bloodstream infections annually in the US.
In some cases, symptomatic persistent infections develop even in the absence of a clear change in the host environment. These pathogens are usually associated with acute infections, but for unclear reasons may establish a more persistent infection in some individuals. For example, recurrent or chronic cystitis is a common consequence of an acute urinary tract infection. In one study, 30% of women experienced at least one culture confirmed recurrence within six months of their initial infection. In some patients recurrent cystitis can become so problematic to necessitate prophylactic or suppressive therapy with antimicrobials. Other examples of symptomatic persistent infections without clearly identifiable host risk factors, aside from obvious anatomic factors, include native-valve endocarditis, osteomyelitis, chronic sinusitis, and otitis media.

**Treatment of persistent infections.** It is clear that there are indications to treat both asymptomatic and symptomatic persistent infections. Unfortunately, the treatment of persistent infections is generally more difficult than the treatment of acute infections. In the case of latent *M. tuberculosis*, the standard treatment regimen requires 9 mo of antibiotics, and treatment of latent syphilis is three times longer than treatment of acute syphilis infection. Chronic *Salmonella Typhi* infection is extremely difficult to eradicate, even with very aggressive antibiotic therapy, and can require removal of the gallbladder. Treatment of device-associated infections often requires removal of the infected device in addition to prolonged courses of antibiotics. Antibiotic therapy against *P. aeruginosa* and *S. aureus* infections in CF patients becomes less and less effective later in the course of disease with increasing resistance in the infecting pathogen, and many patients ultimately succumb to infection despite appropriate antibiotic therapy.

**Why are persistent infections so difficult to treat?** Numerous factors contribute to the difficulty in sterilizing persistent infections. One contributing factor may be that bacteria often establish persistent infections within a “protected niche” in the host. For example, there are specific regions within the host where physical structures may obstruct an effective immune response and prevent adequate penetration with antibiotics, notably the blood-brain barrier, joint spaces and the sinuses. In other cases, the host immune response may actually create a “protected niche” by attempting to sequester the bacteria, exemplified by granulomas. While granuloma formation during *M. tuberculosis* infection represents a mechanism of host-defense, granulomas are also believed to protect bacteria, though incompletely, from antibiotics. Finally, some pathogens may develop their own “protected niche,” either through the formation of bacterial communities known as biofilms or by adapting to intracellular growth. Biofilms are bacterial communities embedded within an extracellular matrix and adherent to a surface, for example a foreign device in the case of device-associated infections, or gallstones in the case of *Salmonella Typhi*. One important characteristic of biofilms is the intrinsic resistance of the bacterial community to the host immune system. This is due to multiple factors, including decreased efficacy of antibodies and antimicrobial peptides against bacteria within biofilms, decreased phagocytic uptake, and decreased sensitivity to polymorphonuclear leukocyte (PMN)-mediated killing. The extracellular matrix component of a biofilm is also believed to partly limit the diffusion of antibiotics. Finally, some persistent infections are associated with intracellular growth, including infection by *M. tuberculosis*, *T. pallidum*, *H. pylori*, and *Salmonella Typhi*. Similar to biofilms, the intracellular environment confers protection from host immune responses including antibodies and complement factors, and may limit the effective concentration of antibiotics presented to bacteria.

Evidence suggests, however, that the concept of a “protected niche” is not sufficient to fully explain persistent infections. For example, some pathogens establish persistent infections in regions of the host that are not considered protective niches. Furthermore, several studies have demonstrated that antibiotics can in fact diffuse through biofilms, and imaging studies with radiolabeled antibiotics demonstrate that antibiotics do successfully penetrate granulomas. Thus, the barrier argument is insufficient to explain the ability of bacteria in these niches to survive chemotherapy.

In addition to sequestration from the immune system and antibiotics, another factor contributing to persistent infection is the ability of bacteria to adopt an altered physiologic state against which current antibiotics that predominantly target replicating cells are less efficacious. Walsh McDermott first suggested the ability of bacteria to “play dead” or transform themselves by “adaptive plasticity” in 1958. He proposed that staphylococci and tubercle bacilli in mice adopt an alternative, reversible state that is “indifferent” to antibiotics. This hypothesis was supported by later work with *M. tuberculosis* in an in vivo mouse infection model. Mice infected with *M. tuberculosis* appear to clear infection after 12 weeks of treatment with multiple antibiotics, as cultures from the homogenized lungs and spleen of these mice are sterile. However, with continued observation, 2/3 of the mice relapse with drug-sensitive bacteria, either spontaneously or with immunosuppression. This observation suggests both that bacteria are present within the host in a non-replicating or slowly replicating state that cannot be easily cultured in vitro, and that antibiotics are relatively ineffective against this physiologic state.

**Models Used to Study Persistent Infections In Vitro**

As efforts have been made to understand the role of altered bacterial physiologic states, specifically non-replicating or slowly replicating states, in persistent infections, several different in vitro models have emerged. Here, we focus on five of these models: facultative intracellular growth, the small colony variant phenotype, a “persisters” subpopulation, environmentally induced antibiotic

---

**www.landesbioscience.com Virulence 275**
indifference, and biofilms. In each of these models, bacteria enter a different physiologic state during persistent infection that is associated with refractoriness to antibiotic-mediated killing. While there are clear differences between these models, this review focuses on recent work establishing increased protection against oxidative stress as a key element across models and pathogens. At the outset we acknowledge that the terminology used in the field to describe these phenomena is confusing and variable. The term antibiotic tolerance is often used in the scientific literature to describe the phenomena of non-heritable antibiotic resistance, but historically antibiotic tolerance has also been used to describe specific cases of heritable resistance. For clarity, in this review we define the term antibiotic tolerance as the reduced efficacy of antibiotics in the absence of genotypic resistance.

**Intracellular pathogens.** Many pathogens involved in persistent infections are facultative intracellular pathogens, including uropathogenic *E. coli* (UPEC), *Salmonella* Typhi and *M. tuberculosis*. For UPEC and *Salmonella* Typhimurium, the data suggests that adaptation to the intracellular environment causes the bacterium to enter a non-replicating state. Helaine et al. used a fluorescence dilution method to quantify bacterial replication of *Salmonella* Typhimurium within macrophages. They found that after entry into macrophages a subset of the initial population did not undergo any replication, suggesting the onset of a non-replicating state. Likewise, UPEC, which is primarily an extracellular pathogen, has been shown to survive intracellularly in a non-replicating state during the course of urinary tract infections and pyelonephritis. During acute infection, UPEC invades superficial epithelial cells. In some cases, the epithelial cells expel the bacteria via a TLR4-dependent pathway. However, some bacteria escape from endocytic vesicles into the cytoplasm and replicate to form intracellular bacterial communities (IBCs). These communities, which have been identified in vivo in women with acute cystitis, are protected from the host immune system, display antibiotic tolerance, and are required for infection. Ultimately, the superficial epithelial cells undergo apoptosis and bacteria contained within IBCs are released. At this point, the acute infection may resolve, or UPEC may establish a persistent infection by invading exposed transitional cells and forming “quiescent intracellular reservoirs”. These bacteria, contained in membrane-bound compartments in bladder transitional cells, do not replicate, but are able to survive for months, even in the face of antibiotic therapy. These reservoirs of bacteria are then thought to represent a source for recurrent or chronic cystitis. Interestingly, the formation of quiescent intracellular reservoirs depends on the severity of the initial immune response during acute infection. It is unclear whether a more severe immune response induces phenotypic changes in bacteria that are more conducive to chronic infection, or whether a more severe immune response simply facilitates chronic infection through damage to the epithelium.

Similar to UPEC, *M. tuberculosis* can replicate intracellularly. However, while UPEC requires specific factors to escape from the endosome prior to active replication, *M. tuberculosis* is able to replicate within the phagosome, expressing specific factors to counteract the harsh conditions encountered in the lysosome. In non-activated macrophages mycobacteria are able to arrest phagosome maturation, preventing fusion with the lysosome. The mechanisms responsible for phagosome arrest are not completely understood, but likely involve multiple factors including mycobacterial cell wall lipids as well as effectors secreted via the ESX and SecA2 secretion systems. In IFN-γ-activated macrophages, phagolysosome fusion and maturation occurs; nevertheless, *M. tuberculosis* is able to survive in this harsh environment. Response to nitric oxide synthesized by the macrophage, the bacterium expresses multiple enzymes and antioxidants to counteract the reactive nitrogen species (RNS) and ROS encountered within the phagolysosome, including the KatG catalase-peroxidase, superoxide dismutases, low molecular weight thiols, and an NADH-dependent peroxidase. Mutants with defects in katG catalase-peroxidase or superoxide dismutases display decreased virulence in mouse infection models, demonstrating that the ability of *M. tuberculosis* to detoxify ROS and RNS is therefore crucial for its survival within the host.

The multiplicity of pathways for ROS and RNI detoxification within *M. tuberculosis* may likely provide protection against bactericidal antibiotics as well, given data implicating ROS in death from bactericidal antibiotics. Evidence supporting this link between the oxidative stress response and antibiotic tolerance was recently described in the intracellular model for persistence using the pathogen *Mycobacterium marinum*. *M. marinum* displays antibiotic tolerance shortly after phagocytosis. This antibiotic-tolerant phenotype was found to depend on the expression of bacterial efflux pumps required for intracellular growth. Efflux pumps have recently been implicated in the oxidative stress response mechanism, perhaps functioning as a mechanism for the bacterium to efflux proteins damaged by ROS. While the upregulation of efflux pumps is classically associated with increased efflux of antibiotics resulting in lower intracellular concentrations, in intracellular mycobacteria, it could also serve both as a mechanism for the bacterium to adapt to intracellular growth as well as provide protection against hydroxyl radical mediated antibiotic killing.

**Small colony variants.** The small colony variant (SCV) phenotype represents another bacterial phenotype associated with persistent infections. First described in *Salmonella* Typhi in 1910, more recent work has associated the SCV phenotype with *P. aeruginosa* and *S. aureus* infection in CF patients. The phenotype, most well studied in *S. aureus*, is associated with smaller colony morphology when plated on agar plates, decreased expression of toxins, increased expression of adhesins, intracellular growth and resistance to antibiotics. The SCV phenotype is associated with a thick cell wall and clinical SCV isolates demonstrate upregulation of genes under the control of the alternative sigma factor SigB that plays a role in oxidative stress response, suggesting that the SCV phenotype may be a defense mechanism against environmental stress. SCV isolates obtained from clinical specimens rapidly revert to a wild-type phenotype when sub-cultured in vitro, complicating the study of this phenomenon. However, mutants in the electron transport chain, either *hemB* or *menD* mutants, mimic the SCV phenotype, and work with these mutants has suggested that the SCV phenotype may
represent an adaptation to facilitate intracellular survival and growth. In support of this hypothesis, *S. aureus hemB* mutants have been reported to survive within the lysosome, and several studies have reported the proliferation and persistent survival of SCV *S. aureus* within endothelial cells. The survival of SCV within endothelial cells may also be a consequence of decreased α-toxin expression and consequently decreased apoptosis of infected cells. Tuchscherer et al. studied a virulent wild-type *S. aureus* clinical isolate in several in vitro and in vivo infection models and found that persistence in all models strongly favored the SCV phenotype.

A mechanism for the rapid switching between SCV and wild-type phenotypes was suggested by Cui et al. after studying a *S. aureus* strain that simultaneously produces both SCVs and normal colony variants. Whole genome sequencing of the two variants revealed that a reversible, large-scale inversion of the chromosome occurs at high frequencies, accounting for the two observed phenotypes. Comparing the expression profiles of the two variants revealed that the SCV was associated with decreased expression of genes involved in thiamine metabolism (required for menadione synthesis, a component of the electron transport chain) as well as oxidative phosphorylation. These findings are consistent with prior observations associating SCV with defects in the respiratory chain. The SCV phenotype is associated with tolerance to antimicrobials, which previously has been attributed to the decreased growth rate and metabolism associated with this phenotype, and decreased antibiotic uptake due to a defect in the electron transport chain. While these may be contributing factors, the association of SCV with defects in the electron transport chain suggests that the SCV phenotype may also be a mechanism to protect the cell against oxidative stress. Repression of the electron transport chain will lead to decreased endogenous free radical production and decreased superoxide stress. The SVC phenotype may therefore protect the bacteria from superoxide stress encountered during intracellular persistence with the additional consequence of protection against bacterial antimicrobials.

**Persisters.** The term “persisters” refers to a small population of bacteria that survives treatment with high doses of antibiotics in the absence of genetic resistance. The phenomenon was first described shortly after scientists began using penicillin to treat bacterial infections. In 1942, Hobby et al. noted that approximately 1% of hemolytic streptococci survived treatment with penicillin in vitro. Joseph Bigger, who similarly discovered that small numbers of *S. aureus* cells consistently survive antibiotic treatment in vitro without developing genetic resistance, then described these surviving bacteria as "persisters". Since these initial observations, persister subpopulations have been observed in many different human pathogens, including *E. coli*, *S. aureus*, *M. tuberculosis*, and *P. aeruginosa* as well as in vivo in several mouse infection models. Examination of persisters in *E. coli* was facilitated by the discovery of the high persistence hipA mutant. *hipA* encodes the toxin in a toxin-antitoxin module, with the antitoxin *hipB* neutralizing *hipA* activity. Expression of *hipA* in excess of *hipB* results in cessation of cell growth; the high persistence *hipA7* mutant has two point mutations resulting in a gain of function and a high persistence phenotype. Balaban et al. used single cell microfluidic studies to characterize persisters in the *hipA7* mutant as well as in a second toxin-antitoxin mutant, *hipQ*, and identified two persister types. Type I persisters are generated during stationary phase and are characterized by a prolonged lag time when transferred to fresh media. Type II persisters are continuously generated by a phenotype-switching mechanism independent of growth phase.

Stochastic processes within the cell are believed to result in the formation of the persisters observed by Balaban et al. Multiple pathways have been suggested for persister formation. One of the first classes of genes implicated in persister formation was toxin-antitoxin (TA) genes such as *hipA7* and *hipQ*. Recent transcriptome profiling of persisters, isolated by collecting cells that failed to lyse after β-lactam or D-cycloserine exposure, has also revealed that several stress response regulons, including the SOS response, as well as several toxin-antitoxin (TA) genes, are upregulated in persister populations in *E. coli* and in *M. tuberculosis*. One mechanism by which TA loci may induce stochastic persistence in *E. coli* was recently described. Many toxin genes, activated upon degradation of the cognate antitoxin, encode mRNases that rapidly degrade mRNA, stopping translation and replication, thereby inducing antibiotic tolerance. The degradation of anti-toxins is mediated by the Lon protease, and stochastic variation in the number of Lon molecules within a cell may affect toxin levels, toxin activity, and therefore persistency rates. More recently, an additional mechanism for stochastic persistence was described by Wakamoto et al. in *Mycobacterium smegmatis* using the antibiotic isoniazid (INH). Single cell microfluidic studies revealed that stochastic expression of KatG, the enzyme required for activation of INH, determined whether a cell survived antibiotic stress.

Recently, several suggested pathways for persister formation implicate a role for oxidative stress in persister formation and survival. Kim et al. observed greater numbers of persisters in *E. coli* subpopulations with normal morphology and lower hydroxyl radical concentrations following antibiotic treatment, compared with filamentous populations with increased hydroxyl radical concentrations, suggesting a role for ROS in persister survival. Oxidative stress is one of several signals that results in induction of the SOS response, which has been shown in *E. coli* to induce both β-lactam and fluoroquinolone antibiotic tolerance. More recently, the small molecule indole, induced by oxidative stress, has been implicated in persister formation. Lee et al. found that exposure to antimicrobials and oxidative stress results in increased indole production through transcriptional upregulation of the *mdaA* gene responsible for indole synthesis. Indole is thus secreted by a small subpopulation of *E. coli* cells in response to antibiotic exposure. Indole then induces transcriptional changes in neighboring cells, most notably upregulation of efflux pumps and oxidative stress protective mechanisms, resulting in antibiotic tolerance in the greater population. In addition, Wu et al. demonstrated that treating an *E. coli* population with the pro-oxidant paraquat results in increased antibiotic tolerance within the population via upregulation of MDR efflux pumps. One possibility suggested by the authors is that
upregulation of the MDR efflux pumps results in an effective decrease in fluoroquinolone concentration, allowing for the survival of a greater number of bacteria. An alternative explanation is that increased expression of MDR efflux pumps, implicated as an important component of the oxidative stress response, may provide increased protection against oxidative stress and facilitate bacterial survival even at the same intracellular concentration of antibiotic.55,56 The importance of the oxidative stress response in persister populations was further highlighted by recent work demonstrating that the persister subpopulation in M. smegmatis and M. tuberculosis is differentiated from the larger antibiotic susceptible population by differential sensitivities to ROS.24 When decreased concentrations of ROS are achieved, either through small (20%) reductions in oxygen tension or with the addition of thiourea, a free radical quencher, the antibiotic tolerant persister population survives antibiotic treatment. In contrast, when increased concentrations of ROS are achieved via redox cycling with the antibiotic clofazamine, the persister population is unable to survive antibiotic treatment.25 It is intriguing to conjecture based on the differential susceptibilities of persisters to ROS in M. smegmatis that the stochastic expression of KatG recently observed in M. smegmatis may affect bacterial survival not only from differential antibiotic activation, but also from enhanced protection against oxidative stress.80

Environmentally induced antibiotic indifference. Environmental stress, for example the deprivation of nutrients, hypoxia or low pH, induces the phenotype of antibiotic indifference, characterized by arrested growth and population-wide antibiotic tolerance.76-102 Similarly, stationary phase bacteria, which encounter the depletion of nutrients and changes in the pH of the media, also exhibit antibiotic indifference. While stationary phase is associated with both "environmentally induced" antibiotic indifference and the generation of type I persisters described above, important differences exist between these two models for antibiotic tolerance. In the case of persisters, stationary phase cells are diluted into fresh media prior to antibiotic challenge and only a minority of the population survives. With antibiotic indifference, the bacteria are held in stationary phase at the time of antibiotic challenge and a majority of the population survives (Fig. 1). It is not known whether a common biological mechanism contributes to these two different antibiotic tolerant phenotypes.

The antibiotic indifferent phenotype observed after nutrient deprivation is associated with a coordinated transcriptional response to carbon and amino acid starvation, called the stringent response. The stringent response is mediated by the production of hyperphosphorylated guanine nucleotides, (p)ppGpp, by the protein RelA.103 The (p)ppGpp molecule synthesized by RelA has multiple roles in the cell, including binding to RNA polymerase and changing transcription factor expression and activity as it coordinates the extensive bacterial response to stress. In addition, (p)ppGpp production is important for the antibiotic tolerance phenotype in vitro. In E. coli relA deletion mutants that are unable to synthesize (p)ppGpp, nutrient starvation does not elicit tolerance to penicillin.104 Conversely, when the relA gene was used to overexpress (p)ppGpp in E. coli, the bacteria exhibited tolerance to penicillin.105 In vivo, work in M. tuberculosis suggests RelA is also required for persistent infection, as bacteria with a relA deletion are significantly impaired in their ability to establish persistent infection in mice. The mechanism linking RelA and persistence has been further supported in recent work by Nguyen et al., who studied a relA deletion mutant in P. aeruginosa and found that the RelA mediated stringent response in P. aeruginosa directly affects antioxidant enzyme expression and decreases production of pro-oxidant molecules.106 Therefore, the coordinated stress response mediated by RelA results in increased protection against oxidative stress, potentially explaining the observed antibiotic tolerant phenotype.

Biofilms. Biofilms are bacterial communities embedded within an extracellular matrix and adherent to a variety of surfaces, including living tissue and indwelling medical devices.28 An extensive exopolysaccharide layer surrounds bacteria within biofilms. This physical barrier is believed to provide protection against environmental stresses like heat-shock and desiccation, as well as against the host immune system.107 Biofilm formation is induced by a variety of stresses, including nutrient limitation, iron limitation, and cell envelope stress. The general stress response, regulated by the alternative sigma subunit of RNA polymerase, RpoS, is important for biofilm formation as deletion of rpoS leads to decreased biofilm formation in E. coli.108 Once biofilms are established, the process of detachment, when planktonic bacteria periodically escape the biofilm, is also regulated.109 Recently, d-amino acids, produced by many bacteria, were shown to break down biofilms and signal for biofilm disassembly.110 The in vivo consequence of biofilm disassembly is bacterial dissemination and the establishment of a new nidus of infection, potentially explaining the natural history of chronic, relapsing infections.109 A caveat to this model, however, is that actual in vivo biofilms or bacterial communities may vary in their resemblance to in vitro biofilms, depending on the type of infection.

Similar to the other three models discussed, bacteria within biofilms display phenotypic antibiotic tolerance, and several links to oxidative stress within biofilms have recently been described. Boles et al. recently showed that bacteria within biofilms experience significant endogenous oxidative stress and consequently upregulate several genes involved in the oxidative stress response, including soxS, a regulator of the superoxide response.111,112 This induction suggests that increased antioxidant responses within biofilms could contribute to the antibiotic tolerant phenotype. A link between antibiotic tolerance and oxidative stress has also been illustrated in the yeast Candida albicans, using a strain with reduced antioxidant capabilities due to the deletion of two superoxide dismutases, Sod4 and 5. The C. albicans deletion strain exhibited significantly less antibiotic tolerance in biofilms compared with the wild-type strain.113 Finally, the work in P. aeruginosa demonstrating a RelA-dependent antioxidant response discussed in the context of antibiotic indifference is also relevant to biofilms. Bacteria within biofilms are relatively starved of nutrients due to reduced diffusion through the biofilm, resulting in induction of the RelA-mediated stringent response with
intracellular bacterial communities in uropathogenic E. coli, as it has been suggested that the intracellular bacterial communities of UPEC are actually organized within biofilms on the surface of intracellular membrane surfaces.22 The complex relationships between the models for persistent infections can also be observed within the larger context of clinical infections, for example, pseudomonas infection in CF patients. P. aeruginosa forms biofilms within the cystic fibrosis lung,17 and P. aeruginosa and S. aureus infections in CF patients are both associated with small colony variant phenotypes. Finally, clinical isolates of P. aeruginosa cultured from CF patients contain increased numbers of “persisters” when tested in vitro.18

**Conclusions**

Many different models have been proposed to explain chronic infections and their associated antibiotic tolerance in the absence of genetic resistance, including facultative intracellular growth, small colony variants, persister populations, environmentally induced antibiotic indifference, and biofilm formation. In light of these complexities, it is important to consider the potential role of biofilms in the persistence and tolerance of antibiotics in chronic infections. Further research is needed to understand the mechanisms by which biofilms contribute to antibiotic tolerance and to develop strategies to overcome this resistance.

---

**Figure 1.** Persistence vs. environmentally induced antibiotic indifference. (A) Type I persistence. Slowly replicating, antibiotic tolerant cells result from passage through stationary phase, and are characterized by an extended lag time after dilution in fresh media (type I persisters). The number of type I persisters observed is directly proportional to the size of the stationary phase inoculum. When the diluted population is exposed to antibiotics the majority of cells die, but the persisters survive. Persister cells are represented by red ovals, and rapidly growing, antibiotic-sensitive cells are represented by white ovals. (B) Type II persistence. Slowly replicating, antibiotic tolerant cells also may be continuously generated during exponential growth (type II persisters). When the population is exposed to antibiotics, the majority of cells die, but the persisters survive. When the surviving cells are re-grown in fresh media, the bacteria regain antibiotic sensitivity as this is a phenotypic change, but new persister cells may be generated. Persister cells are represented by black ovals and rapidly growing, antibiotic-sensitive cells are represented by white ovals. (C) Environmentally induced antibiotic indifference. Slowly replicating or non-replicating, antibiotic-tolerant cells may also result from environmental stresses like hypoxia or carbon starvation, which induce population-wide antibiotic indifference. When the population is exposed to antibiotics, all the cells survive. When the environmental stress is removed, the surviving cells resume growth and regain antibiotic sensitivity as this is a phenotypic, not genetic, change. Environmental-induced antibiotic-tolerant cells are represented by green ovals and rapidly growing, antibiotic-sensitive cells are represented by white ovals. This figure depicts theoretical extremes for persistence and environmental-induced antibiotic indifference. In reality, all three types of antibiotic-tolerant cells can co-exist depending on the conditions of growth and the culture.
Mounting evidence suggests that bacteria confronting host immunity within many different environments are trying to protect themselves from oxidative stress. Thus, it is tempting to hypothesize that the same bacterial adaptive responses to oxidative stresses in the host microenvironment may provide the additional benefit of facilitating bacterial survival during antibiotic exposure. This survival advantage may reflect the physiologic changes occurring in bacteria in response to oxidative stress, of the wide range of experimentally supported models, it is likely that numerous mechanisms, rather than a single one, play a role in the establishment of a chronic infection and the associated difficulty in sterilizing these infections. In this review, we highlight that despite the heterogeneity of the mechanisms contributing to the antibiotic tolerant population, the cellular response to oxidative stress may be a shared theme among the diverse pathways to chronic infections and antibiotic tolerance (Fig. 2).
allowing survival at the same intracellular concentration of antibiotic. Alternatively, the upregulation of efflux pumps as part of the oxidative stress response may decrease the effective intracellular concentration of antibiotics, enabling bacterial survival. The link between the oxidative stress response and persistent infections suggests a new approach to managing persistent infections, regardless of the underlying mechanism. If small molecules can be identified that potentiate oxidative stress or subvert cellular mechanisms that protect against reactive oxygen species, these small molecules have the potential to more effectively sterilize infections that currently defy our antibiotic arsenal. By impairing protective mechanisms against oxidative stress, these “new therapeutics” may serve the dual function of acting on bacteria as primary antibiotics, as well as impairing the bacterial defense to host immunity.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.


